Antiviral Drug Paxlovid Linked to Lower Risk of Hospital Admission

Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.

Among people with mild to moderate COVID-19, addition of nirmatrelvir-ritonavir, also known as Paxlovid to the treatment regime was found to prevent hospitalization, revealed study published in Lancet ID.

“Among Kaiser Permanente //members in Southern California who tested positive for coronavirus infection, receiving Paxlovid within 5 days of the start of COVID-19 symptoms was associated with substantial reductions in the risk of hospital admission or death,” said Sara Tartof, PhD, the senior author of the study and an epidemiologist with the Kaiser Permanente Southern California Department of Research & Evaluation. “These findings are even more notable because in this population with high levels of vaccination, we still see additional benefits of this treatment.”

Omicron Variant of COVID-19
Omicron variant is a mutated strain of coronavirus (SARS-CoV-2) with faster transmissibility and enhanced virulence compared to the original COVID-19 virus.

‘The sooner individuals take antiviral drug Paxlovid upon the onset of COVID-19 symptoms, the more effective the medication can be. ’

Paxlovid is an oral therapeutic drug aimed at reducing the risk for severe outcomes of coronavirus infection. It is manufactured by Pfizer Inc. It currently has emergency use authorization by the U.S. Food and Drug Administration for adults and children 12 and older who are at high risk for progression to severe COVID-19.

COVID-19 Treatment with Anti-viral Drug

The study analyses included patients with positive results from coronavirus tests undertaken in outpatient settings between April 8 and October 7, 2022. In the study population, 7,274 people had received Paxlovid, and 126,152 had not received Paxlovid. It was a time dominated by the omicron subvariants BA.2, BA.4, and BA.5. Overall, 86% of the 133,426 participants had received 2 COVID-19 vaccine doses, and 61% had received 3 or more.

The study found:
Effectiveness in preventing hospital admission or death within 30 days after a positive test was 80% for people who were dispensed Paxlovid within 5 days after symptom onset.

Within the subgroup of patients who were dispensed Paxlovid on the day of their positive COVID-19 test, effectiveness was 90%.

Test your Knowledge on Coronavirus (COVID-19)
Coronavirus is a large positive-strand RNA virus that is surrounded by a protein envelope. The virus obtains its name from the S protein spikes on its surface, which resemble a crown. The overall pattern of increasing coronavirus cases is shown to spike up with the “second wave” of COVID-19.

With spiking effects of the second wave of coronavirus, the best way to keep it at bay is to follow COVID-appropriate safety practices like wearing a mask, regularly cleaning your hands, and coughing into a bent elbow or tissue along with physical distancing (6 feet about 2 arm's length), that may help evade the severity of COVID-19 infection.

Effectiveness declined to 44% for patients who received Paxlovid 6 or more days after symptom onset or for cases not experiencing acute clinical symptoms.

H3N2, Swine Flu, and COVID-19 Make Their Round Abouts in India
H3N2, Swine Flu, and COVID-19 are spreading like wildfire throughout the country.

Overall, for patients who received Paxlovid at any time within their clinical course, effectiveness was 54%.

Effectiveness in preventing intensive care unit admission, mechanical ventilation, or death within 60 days after a positive COVID-19 test was 89% for patients who were dispensed Paxlovid 0 to 5 days after symptom onset, and 84% for people who were dispensed Paxlovid treatment at any time.

Could COVID-19 Cause Face Blindness?
COVID-19 could be causing face blindness and people are not able to recognize their own families.

“However, there is still some benefit to treatment 6 or more days after symptom onset. People should talk with their doctors about the best approach for them.”

Source-Eurekalert